Cabaletta Bio (CABA)
NASDAQ:CABA
US Market

Cabaletta Bio (CABA) Income Statement

287 Followers

Cabaletta Bio Income Statement

Last quarter (Q4 2022), Cabaletta Bio's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Cabaletta Bio's net income was $-15.69M. See Cabaletta Bio’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 54.14M$ 54.14M$ 46.31M$ 33.83M$ 18.68M$ 6.19M
Operating Income
$ -54.14M$ -54.14M$ -46.31M$ -33.83M$ -18.68M$ -6.19M
Net Non Operating Interest Income Expense
$ 1.16M$ 1.16M$ 24.00K$ 494.00K$ 1.74M$ 235.00K
Other Income Expense
-----$ -6.24M
Pretax Income
$ -52.98M$ -52.98M$ -46.29M$ -33.34M$ -16.94M$ -12.20M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -51.38M$ -52.98M$ -46.29M$ -33.34M$ -22.27M$ -12.20M
Basic EPS
$ -1.81$ -1.81$ -1.80$ -1.44$ -4.07$ -0.84
Diluted EPS
$ -1.81$ -1.81$ -1.80$ -1.44$ -4.07$ -0.84
Basic Average Shares
$ 108.71M$ 26.01M$ 21.36M$ 23.15M$ 5.47M$ 14.51M
Diluted Average Shares
$ 117.37M$ 29.34M$ 25.74M$ 23.15M$ 5.47M$ 14.51M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 54.14M$ 54.14M$ 46.31M$ 33.83M$ 18.68M$ 6.19M
Net Income From Continuing And Discontinued Operation
$ -52.98M$ -52.98M$ -46.29M$ -33.34M$ -16.94M$ -12.20M
Normalized Income
$ -52.98M$ -52.98M$ -46.29M$ -33.34M$ -16.94M$ -12.20M
Interest Expense
------
EBIT
$ -54.14M$ -54.14M$ -46.31M$ -33.83M$ -18.68M$ -6.19M
EBITDA
$ -52.96M$ -52.96M$ -45.58M$ -33.48M$ -18.58M$ -6.19M
Currency in USD

Cabaletta Bio Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis